REVIEW article
Front. Oncol.
Sec. Molecular and Cellular Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1580515
This article is part of the Research TopicInterplay of Immunity and ECM in CancerView all 6 articles
Exploring a New Direction in Targeted Cancer Therapy Through Hyperbaric Oxygen Therapy Combined with Biomedical Engineering Techniques
Provisionally accepted
- Department of Rehabilitation Medicine, the First Affiliated Hospital of Dalian Medical University, Dalian, China; College of Health-Preservation and Wellness, Dalian Medical University, Dalian, China., First Affiliated Hospital, Dalian Medical University, Dalian, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The hypoxic tumor microenvironment and dense extracellular matrix (ECM) are key factors limiting the effectiveness of cancer treatments. Hyperbaric oxygen therapy (HBOT) effectively alleviates hypoxia by increasing the oxygen partial pressure (pO₂) in tumor tissues, enhancing the sensitivity of chemotherapy, radiotherapy, and immunotherapy. In recent years, the rapid development of biomedical engineering technologies such as nanodrug delivery, engineered bacteria, and immunocellular therapy has provided new strategies to address issues like poor drug penetration and immunosuppressive microenvironments.Studies have shown that the combined application of HBOT and biomedical engineering technologies can synergize: on one hand, HBOT induces reactive oxygen species (ROS) generation and regulates matrix metalloproteinase (MMPs) expression, degrading collagen and fibronectin in the ECM, reducing tumor stiffness, increasing nanodrug penetration depth by 1.8 times and immune cell infiltration rate by 2.3 times. On the other hand, biomedical engineering technologies target delivery of chemotherapy drugs (such as temozolomide/porous silicon nanoparticles), photosensitizers, or gene editing tools (such as CRISPR-Cas9) in conjunction with the improved oxygenation microenvironment by HBOT, significantly enhancing the anti-tumor effects.This article provides a systematic review of the mechanisms, clinical translation outcomes, and safety issues of HBOT combined with biomedical engineering technologies, and highlights the future focus on optimizing individualized treatment plans, long-term efficacy evaluation, and molecular mechanism analysis to promote the clinical application of this interdisciplinary treatment model.
Keywords: hyperbaric oxygen therapy, biomedical engineering technology, cancer treatment, Extracellular Matrix, Nanodrug delivery
Received: 20 Feb 2025; Accepted: 16 May 2025.
Copyright: © 2025 Mei, Han, Yi, Liu and Gong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yong Liu, Department of Rehabilitation Medicine, the First Affiliated Hospital of Dalian Medical University, Dalian, China; College of Health-Preservation and Wellness, Dalian Medical University, Dalian, China., First Affiliated Hospital, Dalian Medical University, Dalian, China
Xiaoyang Gong, Department of Rehabilitation Medicine, the First Affiliated Hospital of Dalian Medical University, Dalian, China; College of Health-Preservation and Wellness, Dalian Medical University, Dalian, China., First Affiliated Hospital, Dalian Medical University, Dalian, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.